What is Asceneuron?
Founded in 2012 and headquartered in Lausanne, Switzerland, Asceneuron is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecules. The company’s core mission is to halt and prevent the molecular events that trigger neurodegenerative diseases, including orphan tauopathies, Alzheimer’s, and Parkinson’s. By focusing on precision medicine and novel biological pathways, Asceneuron has established itself as a key player in the European biotech ecosystem, bridging the gap between fundamental research and patient-centric therapeutic solutions.
How much funding has Asceneuron raised?
Asceneuron has raised a total of $130.6M across 2 funding rounds:
Series A
$30.6M
Series C
$100M
Series A (2015): $30.6M with participation from SR One, Sofinnova Partners, Kurma Partners, and MS Ventures
Series C (2024): $100M led by OrbiMed, Novo Holdings, and SR One
Key Investors in Asceneuron
OrbiMed
OrbiMed is a specialized healthcare investment firm with deep expertise across biopharmaceuticals and medical devices, managing capital to support companies from early-stage ventures to established organizations.
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focused on long-term value creation in the life sciences sector.
SR One
SR One is a transatlantic biotechnology venture capital firm that partners with scientific teams to translate innovative discoveries into new medicines, providing both strategic and operational support.
What's next for Asceneuron?
With the infusion of capital from its latest funding round, Asceneuron is poised to scale its clinical development programs and expand its research capabilities. The strategic focus will likely center on advancing its lead candidates through rigorous clinical trials while strengthening its intellectual property portfolio. As the company transitions into a more mature phase of its lifecycle, the emphasis will shift toward validating its therapeutic efficacy in human populations and exploring potential commercialization pathways. The continued backing from top-tier life sciences investors provides the necessary operational runway to navigate the complex regulatory landscape of neurodegenerative drug development, ultimately aiming to deliver life-altering treatments to patients suffering from debilitating brain disorders.
See full Asceneuron company page
